GlassScriptPhysician profile
Waseem N Ibrahim
NPI 1346291374
$2,517.37
in general payments reported to CMS, 2019-2025
22 companies · $39.24 in 2025
The $39.24 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $121 · 2021: $80.34 · 2022: $324 · 2023: $441 · 2024: $565 · 2025: $39.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $906.33 | 2019-2024 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $691.44 | 2019-2024 | |
| Ucb, INC. | $164.31 | 2019-2020 | |
| Emd Serono, INC. | $111.72 | 2019-2020 | |
| Amgen INC. | $103.65 | 2019-2020 | |
| Mdd US Operations, LLC | $79.29 | 2019-2024 | Gocovri |
| Allergan, INC. | $56.37 | 2019-2020 | |
| Abbvie INC. | $50.26 | 2019-2023 | |
| Csl Behring | $49.08 | 2024 | Hizentra |
| Eisai INC. | $40.77 | 2019-2020 | |
| Biogen, INC. | $39.24 | 2025 | Leqembi |
| Takeda Pharmaceuticals U.S.A., INC. | $38.20 | 2021-2023 | Gammagard |
| Genentech USA, INC. | $33.08 | 2022 | |
| Argenx US, INC. | $29.68 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Adamas Pharmaceuticals, INC. | $22.74 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.47 | 2019 | |
| Lilly USA, LLC | $18.12 | 2019 | |
| Livanova USA, INC. | $17.53 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.46 | 2019 | |
| Sk Life Science, INC. | $13.23 | 2024 | |
| Supernus Pharmaceuticals, INC. | $11.22 | 2019 | |
| Travere Therapeutics, INC. | $1.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waseem Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.